G01N 2333/5406
Il-4
G01N2333/5406 (Il-4) appears on 42 US grants and 79 published applications in this corpus.
Search patents in G01N- Granted patents
- 42
- Published applications
- 79
- Assignees
- 64
- Inventors
- 196
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 5 |
| 2005 | 1 | 2 |
| 2006 | 0 | 1 |
| 2007 | 2 | 2 |
| 2008 | 2 | 3 |
| 2009 | 1 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 1 | 2 |
| 2013 | 0 | 3 |
| 2014 | 2 | 1 |
| 2015 | 0 | 6 |
| 2016 | 1 | 3 |
| 2017 | 1 | 5 |
| 2018 | 6 | 2 |
| 2019 | 0 | 2 |
| 2020 | 5 | 8 |
| 2021 | 3 | 4 |
| 2022 | 1 | 5 |
| 2023 | 1 | 6 |
| 2024 | 0 | 7 |
| 2025 | 5 | 5 |
| 2026 | 4 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for classifying an allergic patient as eligible to allergen immunotherapy8 Sep 2026US 12,730,114 B2Stallergenes Greer International AG
- Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)11 Aug 2026US 12,702,710 B2Medicenna Therapeutics Inc.
- Cytokine-based therapies and methods30 Jun 2026US 12,668,627 B2Reverb Therapeutics, Inc.
- Method for measuring systemic chronic inflammaging6 Jan 2026US 12,517,135 B2Edifice Health, Inc.
- IL4/IL13 receptor molecule for veterinary use30 Sep 2025US 12,428,466 B2Elanco US Inc.
- Novel cytokine-based therapies and methods17 Sep 2026US 2026/0274943 A1Reverb Therapeutics, Inc.
- Mmp-14 or timp potency assay for mesenchymal stem cells15 Jan 2026US 2026/0014205 A1Longeveron Inc.
- Biomarkers for allergen immunotherapy1 Jan 2026US 2026/0002930 A1Alfred Health
- Novel cytokine-based therapies and methods9 Oct 2025US 2025/0313620 A1Reverb Therapeutics, Inc.
- Novel cytokine-based therapies and methods9 Oct 2025US 2025/0314662 A1Reverb Therapeutics, Inc.
Most cited
By later US patents
- Assessing immunological state of transplant recipients19US 6,150,121 AWisconsin Alumni Research Foundation · 2000
- Human interleukin-4 antagonist/agonist screens12US 5,958,707 ASchering Corporation · 1999
- Diagnostic and therapeutic methods based upon V.alpha.24J.alpha.QT cells7US 6,162,609 AThe Brigham and Women S Hospital, Inc. · 2000
- De novo design of potent and selective interleukin mimetics5US 10,703,791 B2The Board of Trustees of the Leland Stanford Junior University · 2020
- De novo design of potent and selective interleukin mimetics5US 10,844,105 B2The Board of Trustees of the Leland Stanford Junior University · 2020